A Robust Approach to Enhance Tumor-selective Accumulation of Nanoparticles

While nanoparticles have shown great promise as drug carriers in cancer therapy, their effectiveness is critically dependent on the structural characteristics of the tumor vasculature. Here we demonstrate that several agents capable of inducing vascular responses akin to those observed in inflammatory processes enhance the accumulation of nanoparticles in tumors. The vascular-active agents tested in this study included a bacterium, a pro-inflammatory cytokine, and microtubule-destabilizing drugs. Using radiolabeled nanoparticles, we show that such agents can increase the tumor to blood ratio of radioactivity by more than 20-fold compared to nanoparticles alone. Moreover, vascular-active agents dramatically improved the therapeutic effect of nanoparticles containing radioactive isotopes or chemotherapeutic agents. This resulted in cures of animals with subcutaneous tumors and significantly prolonged the survival of animals with orthotopic brain tumors. In principle, a variety of vascular-active agents and macromolecular anticancer formulations can be combined, which makes this approach broadly applicable and particularly suited for the treatment of patients who have failed standard therapies.

[1]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[2]  F. Balkwill.  Tumour necrosis factor and cancer , 2009, Nature Reviews Cancer.

[3]  E. Schwartz.  Antivascular Actions of Microtubule-Binding Drugs , 2009, Clinical Cancer Research.

[4]  H. Maeda,et al.  Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[5]  A. Eggermont,et al.  Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response. , 2007, Cancer research.

[6]  K. Kinzler,et al.  Spore Coat Architecture of Clostridium novyi NT Spores , 2007, Journal of bacteriology.

[7]  K. Hynynen,et al.  Chemotherapy delivery issues in central nervous system malignancy: a reality check. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  B. Coiffier.  Rituximab therapy in malignant lymphoma , 2007, Oncogene.

[9]  Xin Huang,et al.  A Bacterial Protein Enhances the Release and Efficacy of Liposomal Cancer Drugs , 2006, Science.

[10]  G. Parmigiani,et al.  The genome and transcriptomes of the anti-tumor agent Clostridium novyi-NT , 2006, Nature Biotechnology.

[11]  V. Torchilin,et al.  Micellar Nanocarriers: Pharmaceutical Perspectives , 2006, Pharmaceutical Research.

[12]  J. Barbet,et al.  High-Activity Radio-Iodine Labeling of Conventional and Stealth Liposomes , 2006, Journal of liposome research.

[13]  Armando Santoro,et al.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.

[14]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[15]  Kenneth J. Hillan,et al.  Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.

[16]  Jun Fang,et al.  Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. , 2003, International immunopharmacology.

[17]  E. Montserrat.  Rituximab in chronic lymphocytic leukemia. , 2003, Seminars in oncology.

[18]  C. Kanthou,et al.  The biology of the combretastatins as tumour vascular targeting agents , 2002, International journal of experimental pathology.

[19]  K. Kinzler,et al.  Combination bacteriolytic therapy for the treatment of experimental tumors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[20]  M. Bibby,et al.  Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model , 2001, British Journal of Cancer.

[21]  D. Papahadjopoulos,et al.  Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. , 1999, Pharmacological reviews.

[22]  B. Storer,et al.  Biological and clinical effects of intravenous tumor necrosis factor-alpha administered three times weekly. , 1991, Cancer research.

[23]  B. Weichman.  Inflammation: basic principles and clinical correlates , 1988, Agents and Actions.

[24]  H. Dvorak.  Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. , 1986, The New England journal of medicine.

[25]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[26]  E. Frei,et al.  Dose: a critical factor in cancer chemotherapy. , 1980, The American journal of medicine.

[27]  R L Kassel,et al.  An endotoxin-induced serum factor that causes necrosis of tumors. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[28]  W. Hunter,et al.  The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent. , 1973, The Biochemical journal.

[29]  D. Rall,et al.  Studies on the chemotherapy of experimental brain tumors: development of an experimental model. , 1970, Cancer research.

[30]  B. Druker,et al.  Imatinib as a paradigm of targeted therapies. , 2004, Advances in cancer research.

[31]  Ennis,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.